Seeking Alpha

More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6%...

More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6% Y/Y, on a 14% increase in product sales. Operating expenses -24%, R&D expenses -26%, and SG&A expenses -16%, all of which helped to boost bottom line margins.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|